financial: Access Pharmaceuticals Investor Call Tomorrow, Wednesday April 4th at... -- DALLAS and NEW YORK, April 3, 2012 /PRNewswire/ --

Access Pharmaceuticals Investor Call Tomorrow, Wednesday April 4th at... -- DALLAS and NEW YORK, April 3, 2012 /PRNewswire/ --

"....Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas......"

press release: Access Pharmaceuticals, Inc. Presents MuGard Clinical Experience at MASCC Conference - MarketWatch

"MuGard is indicated in Europe for the prevention and management of oral mucositis, and has been used by over 2,000 cancer patients globally. A total of 185 documented patients from various studies utilized MuGard in both prophylactic and curative settings"

MuGard (oral mucositis - U.S.) Access Pharma Initiates US MuGard Sampling Program with Leading Oncology Groups - MarketWatch

"...Sampling efforts for the company include providing large oncology groups with MuGard kits containing six weeks' worth of MuGard therapy for patients undergoing radiation and chemotherapy. Through these oncology groups, Access Pharma initially will provide 500 patients throughout 20 top metropolitan areas full courses of therapy to protect them from oral mucositis."